Skip to main content
SpringerLink
Log in

Disproportionality analysis: skin toxicities with CDK 4/6 inhibitors

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Raschi E, et al. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. American Journal of Clinical Dermatology : 26 Oct 2021. Available from: URL: https://doi.org/10.1007/s40257-021-00645-0

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Disproportionality analysis: skin toxicities with CDK 4/6 inhibitors. Reactions Weekly 1880, 7 (2021). https://doi.org/10.1007/s40278-021-04841-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-04841-3

Search

Navigation